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Abstract
Three articles in this issue of Genetics in Medicine describe examples of “knowledge integration,” 
involving methods for generating and synthesizing rapidly emerging information on health-related 
genomic technologies and engaging stakeholders around the evidence. Knowledge integration, the 
central process in translating genomic research, involves three closely related, iterative 
components: knowledge management, knowledge synthesis, and knowledge translation. 
Knowledge management is the ongoing process of obtaining, organizing, and displaying evolving 
evidence. For example, horizon scanning and “infoveillance” use emerging technologies to scan 
databases, registries, publications, and cyberspace for information on genomic applications. 
Knowledge synthesis is the process of conducting systematic reviews using a priori rules of 
evidence. For example, methods including meta-analysis, decision analysis, and modeling can be 
used to combine information from basic, clinical, and population research. Knowledge translation 
refers to stakeholder engagement and brokering to influence policy, guidelines and 
recommendations, as well as the research agenda to close knowledge gaps. The ultrarapid 
production of information requires adequate public and private resources for knowledge 
integration to support the evidence-based development of genomic medicine.
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Rapid discoveries in genomics and other “omic” fields are creating expectations that new 
tests and interventions will be developed for use in clinical practice and disease prevention.1 
Cancer has been at the forefront of clinical applications of these technologies, which offer 
the potential to use germ-line and tumor genomic data to develop personalized 
interventions.2 Despite this promise, the information needed to move applications into 
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clinical practice is often scarce and stakeholders sometimes disagree on how much evidence 
is needed.3
In this issue of Genetics in Medicine, three articles tackle the complexities of gathering, 
evaluating, and disseminating the evidence on genomic tests. Two articles stem from a 
National Cancer Institute initiative on comparative effective research in cancer genomics 
and personalized medicine.4 Comparative effective research arose as a result of increased 
interest in measuring patient-centered health outcomes and comparing alternative 
approaches to disease prevention and treatment.5 Genomic medicine provides an ideal 
opportunity to apply comparative effective research methods to compare genomic tools and 
applications with usual care in real-world settings.6
In the first article, Goddard et al.7 identify approaches to assessing genomic applications 
through literature reviews and demonstrate lessons learned from the National Cancer 
Institute initiative. Using case studies, they identify significant challenges in the conduct and 
evaluation of comparative effective research, including the rapid pace of innovation and data 
acquisition, lack of oversight, and variable evidentiary thresholds for clinical and personal 
utility. They conclude that a variety of methodological approaches are needed to develop 
and synthesize the knowledge needed to ensure an effective translation of genomic 
discoveries in cancer. These approaches include a combination of comparative observational 
studies and randomized trials, as well as decision modeling and economic analysis of 
patient-centered outcomes.
In the second article, Deverka et al.8 explore how stakeholders view knowledge about 
genomic applications in cancer. Stakeholders include clinicians, insurers, test developers, 
advocates, policy makers, and others whose views can influence translation from research to 
practice. Using case studies, the authors present results of evidence synthesis to 22 diverse 
stakeholders who participated in a workshop to explore the evidence of cancer genomic tests 
for clinical practice and coverage decision-making. Describing how the stakeholders’ 
opinions on evidentiary thresholds diverged and changed during the workshop, the authors 
highlight the need for ongoing stakeholder engagement in unbiased settings. A common 
understanding of the existing evidence base should guide the development of evidentiary 
thresholds in genomic medicine.
In the third article, Wallace et al.9 explore a new way to rapidly update the evidence base on 
genomic applications in practice. Systematic reviews and meta-analyses, the principal tools 
for evidence synthesis, are labor intensive and time consuming; thus, the volume and rapid 
evolution of information in genomic medicine presents a substantial challenge. The authors 
demonstrate an approach to mining curated, online knowledge bases that can reduce the 
burden of updating systematic reviews. Their findings provide important impetus for the 
development and deployment of modern approaches based on text or data mining and other 
technologies to reduce the labor necessary to produce and maintain systematic reviews in the 
rapidly developing field of genomic medicine.
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KNOWLEDGE INTEGRATION AT THE CENTER OF GENOMIC MEDICINE
Each of these three articles addresses a different component of the “knowledge integration” 
(KI) process, a term that has been used to mean different things in different contexts.10,11 
Burke et al.12 viewed KI within and across disciplines as the engine for the effective use of 
genomic information to improve health. They defined KI as “the process of selecting, 
storing, collating, analyzing, integrating and disseminating information both within and 
across disciplines for the benefit of population health. It includes methodological 
development, and is the means by which information is transformed into useful 
knowledge.”12
Because genomic discoveries result from basic, clinical, and population research, KI is at the 
center of translational activities in genomic medicine as illustrated in the T1–T4 
translational pathway discussed elsewhere13 and elaborated here in Figure 1. Translational 
research proceeds in phases, using basic genome-based discoveries to develop promising 
applications such as tests and drugs (T1), evaluating efficacy of such applications and 
developing evidence-based recommendations (T2), implementing and disseminating 
evidence-based recommendations into clinical and public health programs (T3), and 
measuring effectiveness and cost-effectiveness of genomic applications at the population 
level (T4). Most funded and published genomic research, even in cancer, remains either in 
the discovery or early translation phases14 and the evidence base for genomics in practice 
remains limited. The sheer volume and variety of information accumulating from primary 
research creates tremendous potential noise.15
A robust KI process is needed to digest this information and transform it into knowledge that 
drives policy, practice, and further research. Three essential components constitute the 
essence of KI: knowledge management (KM), knowledge synthesis (KS), and knowledge 
translation (KT; Table 1 and Figure 1). These are common to all areas of biomedical 
research and genomics is no exception; however, the volume of new genomic information 
and the speed with which it is developing has the potential to affect all areas of medicine and 
public health.
KM: HORIZON SCANNING AND INFOVEILLANCE
The first component of KI is KM, which is a continuous process of horizon scanning to 
select, store, curate, and track relevant information from multiple disciplines and phases of 
translation. Bioinformatics tools can help automate the process of mining for information on 
genomic discoveries and their potential functional significance, as well as raise hypotheses 
about potential therapeutic or preventive interventions. The National Center for 
Biotechnology Information of the National Library of Medicine has organized a wealth of 
diverse information in open-access, online databases focused primarily on basic research; 
these include genomic sequencing databases, functional databases, and locus-specific 
databases.16
Developing methods for horizon scanning and surveillance of relevant information is part of 
the new field of “infoveillance”.17 An example of this approach is the Human Genome 
Epidemiology Navigator (HuGE Navigator18), a continuously updated, curated knowledge 
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base of published genetic association studies maintained by the Centers for Disease Control 
and Prevention. The number of such publications has quadrupled over the past 10 years, 
with >9,500 articles published in 2011 alone.19 The HuGE Navigator uses a combination of 
text-mining algorithms and human curation,20 which is also the approach taken by Wallace 
et al.9 By placing a wealth of genetic association information at the fingertips of researchers 
and other users, such online applications can improve the efficiency and reduce the time 
required for KS.
The infoveillance approach can be applied to subsequent stages of translation. For example, 
the evaluation of genomic tests requires information on analytic performance, clinical 
validity, clinical utility, and ethical and legal issues.21 The Genomic Applications in Practice 
and Prevention Knowledge Base of the Centers for Disease Control and Prevention is a 
continuously updated database of emerging genomic tests proposed for use in clinical or 
public health practice.22 Between October 2009 and January 2012, >400 newly introduced 
tests were added to the database; approximately two-thirds of these tests were related to 
cancer.22 We have combined cancer- related information from the HuGE Navigator and the 
Genomic Applications in Practice and Prevention Knowledge Base into a trial version of 
CancerGEM KB,23 which will be developed further in the next few years. This year, the 
National Institutes of Health plans to release the Genetic Testing Registry, which will 
provide public access to information submitted voluntarily by test developers.24
KS: SYSTEMATIC REVIEWS, META-ANALYSES, AND MODELING
While KM is an essential first step in the KI process, a crucial second step is KS, which 
“makes sense” of the incoming information and transforms it into information that answers 
specific questions both within and across different scientific disciplines (Table 1 and Figure 
1). For example, within the realm of genetic associations, it is important to know whether or 
not a reported genetic association has been replicated across multiple populations and the 
magnitude of disease risks conferred by specific genetic variants in different populations. In 
the pre–genome-wide association studies era, candidate gene analyses often led to 
nonreplicable results.25 The problem has been partially alleviated by the use of large-scale 
consortia and networks with sufficient sample size to conduct rigorous replication and meta-
analysis. The National Human Genome Research Institute curates an online knowledge base 
of genome-wide association studies results, integrated with other information from the 
National Center for Biotechnology Information.26
KS applies technical methods for systematic review of published and unpublished data using 
a priori rules of evidence. KS may include meta-analysis, decision analysis, and modeling to 
combine information from different study designs and different domains in basic, clinical 
and population research (e.g., Cochrane collaboration reviews;27 Agency for Healthcare 
Research and Quality funded evidence-practice centers28). The independent, 
multidisciplinary Evaluation of Genomic Applications in Practice and Prevention working 
group29 has developed evidentiary rules for conducting comprehensive systematic reviews 
of the analytic validity, clinical validity, and clinical utility of genomic tests in specific 
clinical scenarios.
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In the arena of pharmacogenomics, the Pharmacogenomics Knowledge base (PharmGKB, 
http://www.pharmgkb.org/) has for >10 years created a repository of primary data as well as 
tools to track associations between genes and drugs, and to catalog the location and 
frequency of genetic variations related to drug response.30 With the explosion of new data 
over the past 10 years, PharmGKB now focuses on curating and synthesizing knowledge, 
and captures more complex relationships between genes, variants, drugs, diseases, and 
pathways.
In general, KS can be slow and tedious and is often criticized for this reason. As suggested 
by Goddard et al.7 and Veenstra et al.,31 additional tools could be used in the rapidly 
developing landscape of genomic medicine, including value of information analysis, 
decision analysis, and modeling. All these tools can supplement but not replace synthesis of 
empirical data from observational studies and clinical trials. Methods for rapid review and 
display of existing information are in development. To accelerate KS for genomic tests, the 
Centers for Disease Control and Prevention recently launched an online publication through 
the open-access Public Library of Science. The collection, entitled Public Library of Science 
Currents: Evidence on Genomic Tests, Public Library of Science32 is intended as a rapid 
publication channel for synopses of knowledge on genomic tests. KS is often used by 
independent panels to develop evidence-based recommendations and practice 
guidelines.29,33–35 Much more methodological work is needed to accelerate the pace of KS.
KT: BROKERING INFORMATION TO INFLUENCE RESEARCH, POLICY, AND 
PRACTICE
The third component of KI is KT. Deverka et al.8 clearly illustrate that synthesized 
knowledge tends to be viewed differently by various stakeholders. If genomic medicine is to 
succeed, a strong KT process is crucial. KT is the active process of disseminating 
synthesized information to influence policy, guideline development, practice, and research 
across the translation continuum. This is the most “messy” component of KI because using 
information to influence research and practice requires “buy-in” from stakeholders with 
different perspective and can be an iterative process.
Evidence-based recommendations are necessary but not sufficient to move genomic 
medicine applications into practice. Many forces can affect their diffusion, adoption, and 
implementation. These forces often operate independently of knowledge synthesis and span 
a wide spectrum, including private investments in research and development, policy and 
legal frameworks, oversight and regulation, product marketing, coverage and 
reimbursements, consumer advocacy, provider awareness, access, and health services 
development and implementation. Deverka et al.8 demonstrate once again that payers 
generally require a higher level of evidence of clinical utility than genomic researchers or 
test developers. Issues around differential access and implementation lead to the 
phenomenon of “lost in translation” in clinical practice.36 Furthermore, translation requires 
implementation sciences, health services, and outcomes research agendas (T3 and T4 
research) that are currently underrepresented in funding and publications of genomics 
research.37
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An important component of KT is the convening of stakeholders around KS to address 
differences in evidentiary thresholds that can drive decision making.38 Such collaborations 
link researchers and policy makers, facilitate interactions, understand goals and professional 
culture, and forge new partnerships to use evidence from existing knowledge and define 
areas for future research. This process, sometimes called “knowledge brokering,” is 
ultimately about developing and using evidence-based decision-making to deliver genomic 
medicine in clinical and public health settings. To be successful, KT needs to lead to 
evidentiary standards and empower independent, transparent appraisal of the evidence. 
Examples of such collaborations include the Institute of Medicine round-table on translating 
genomics into health39 and the Genomic Applications in Practice and Prevention,40 a 
collaboration of multiple groups including government agencies, the private sector, 
academia, consumers, and clinical and public health practice.5
In the arena of pharmacogenomics, the Clinical Pharmacogenetics Implementation 
Consortium was formed in late 2009 to develop and publish peer-reviewed guidelines with 
simultaneous posting to PharmGKB with supplemental information.41. The goal of Clinical 
Pharmacogenetics Implementation Consortium is to address some of the barriers to 
implementation of pharmacogenetic tests into clinical practice. Clinical Pharmacogenetics 
Implementation Consortium guidelines are designed to help clinicians understand how 
available genetic test results should be used to optimize drug therapy, rather than if such 
tests should be ordered, thus informing the stakeholder dialogue on evidence-based 
implementation of pharmacogenomics testing in clinical practice.
CONCLUSION
The three papers in this issue7–9 illustrate why a robust KI process is needed to drive the 
growth and development of genomic medicine for years to come. Here, we have elaborated 
on the three components of KI: management, synthesis, and translation. Because of the rapid 
emergence of complex “omic” data from basic, clinical, and population research, we believe 
an adequately resourced KI process with as much automation as possible is needed to keep 
up with the avalanche of information. A multistakeholder KI enterprise should involve both 
the public and private sectors to ensure a rapid, transparent and credible process than can 
drive policy and practice.
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Components of knowledge integration in genomic medicine. Modified from Khoury et al.13
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Table 1
Components of knowledge integration in genomic medicine: definitions and examples
Component Definition Examples
Knowledge management Process of scanning, selecting, storing, curating, and 
tracking genomic research information from multiple 
disciplines and phases of translation
Curated literature and Web-based databases, e.g., HuGE 
Navigator for genetic-epidemiology studies;18 GAPPKB 
to find new genomic tests and link with available 
studies;22,23 Genetic Testing Registry24
Knowledge synthesis Systematic review of information from multiple 
disciplines to assess validity and utility of 
information; process usually employs methods of 
meta-analysis and can use modeling of value of 
information, using direct and indirect evidence
AHRQ evidence-based reviews;28 Cochrane reviews;27 
CancerGEMKB;23 EGAPP reviews and 
recommendations;29 PharmGKB;30 PLoS Currents: 
evidence on genomic tests;32 NIH consensus 
conferences;33 US Preventive Services Task Force;34 
National Institute for Clinical Excellence35
Knowledge translation Process of actively disseminating synthesized 
information to influence policy, guideline 
development, and research across the translation 
continuum, as well as clinical and public health 
practice. The process uses stakeholder engagement 
and knowledge brokering
IOM roundtable on translating genome-based research for 
health;39 the Genomic Applications in Practice and 
Prevention Network;40 Clinical Pharmacogenetic 
Implementation Consortium41
AHRQ, Agency for HealthCare Research and Quality; CancerGEM KB, Cancer Genomic Evidence-based Medicine Knowledge Base; EGAPP, 
Evaluation of Genomic Applications in Practice and Prevention; GAPPKB, Genomic Applications in Practice and Prevention Knowledge Base; 
HuGE Navigator, Human Genome Epidemiology Navigator; IOM, Institute of Medicine; PharmGKB, Pharmacogenomics Knowledge Base.
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